Related Experiment Video
Updated: Jan 13, 2026

Encapsulation Thermogenic Preadipocytes for Transplantation into Adipose Tissue Depots
Published on: June 2, 2015
Alleviating Mechanism of Microencapsulated Compound Probiotics Against Obesity via PPAR Metabolic Pathway
Yuying Ma1, Shuqin Yan1, Yan Dong1
1Engineering Research Center of Agricultural Microbiology Technology, Heilongjiang Provincial Key Laboratory of Plant Genetic Engineering and Biological Fermentation Engineering for Cold Region & Key Laboratory of Microbiology, College of Heilongjiang Province & School of Life Sciences, Ministry of Education, Heilongjiang University, Harbin, 150080, China.
None:
Obesity is a global health challenge, but current pharmacological interventions (e.g., orlistat) often cause adverse effects. Although probiotics show potential in alleviating obesity, the mechanisms by which microencapsulated compound probiotics exert anti-obesity effects via peroxisome proliferator-activated receptors (PPARs) remain unclear. Our previous study demonstrated that pectin beads encapsulating compound probiotics (Lactiplantibacillus plantarum, Limosilactobacillus fermentum, Bifidobacterium breve) exhibited superior anti-obesity effects to single strain in high-fat diet (HFD)-fed rats. Here, we systematically investigated the alleviating effects of these microencapsulated compound probiotics (1 × 10⁸ CFU/day, oral gavage) against HFD-induced obesity in C57BL/6J mice (8-wk intervention) via PPARs-mediated regulatory mechanisms, with orlistat (24 mg·kg- 1·day- 1, oral gavage) as the positive control. Results showed that the microencapsulated compound probiotics significantly reduced weight gain rate (35.68% vs. 58.51% in HFD group, P < 0.05) without affecting food intake, improved hepatic steatosis (reduced hepatocyte vacuolation), and maintained glucose homeostasis (oral glucose tolerance test AUC: 14205 vs. 2150 mg·min/dL in HFD group, P < 0.05). Compared to HFD controls, the probiotics significantly reduced serum total cholesterol (2.90 vs. 6.31 mM, P < 0.05) and interleukin-6 (IL-6: 10.04 vs. 17.66 pg/mL, P < 0.05). Mechanistically, the probiotics downregulated PPAR-γ (0.65-fold vs. HFD, P < 0.05) to inhibit adipogenesis. 16 S rRNA sequencing revealed that the probiotics preserved gut microbial diversity (Shannon index: 5.2 vs. 4.1 in HFD group, P < 0.05), whereas orlistat caused gut dysbiosis (Shannon index: 3.8, P < 0.05 vs. ND group). Together, these findings clarified that microencapsulated compound probiotics alleviate obesity via PPAR-mediated lipid metabolism regulation, while protecting gut ecology-offering a safe and effective microecological strategy for obesity prevention.
Related Concept Videos
Hormonal Regulation
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Regulation of Food Intake
GPCRs Regulate Adenylyl Cylase Activity
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Obesity

